TY - JOUR
T1 - Taxol
T2 - A novel investigational antimicrotubule agent
AU - Rowinsky, Eric K.
AU - Cazenave, Lorranie A.
AU - Donehower, Ross C.
N1 - Funding Information:
Received March 5, 1990; revised May 8, 1990; accepted May 9, 1990. E. K. Rowinsky is the recipient of an American Cancer Society Career Development Award. E. K. Rowinsky, R. C. Donehower, Division of Pharmacology and Experimental Therapeutics, The Johns Hopkins Oncology Center, Baltimore, Md. L. A. Cazenave, Investigational Drug Branch, Cancer Therapy and Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, Md. Correspondence to: Eric K. Rowinsky, M.D., Division of Pharmacology and Experimental Therapeutics, The Johns Hopkins Oncology Center, 600 N. Wolfe St., Baltimore, MD 21205.
PY - 1990/8/1
Y1 - 1990/8/1
N2 - Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades-until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatin-resistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development. [J Natl Cancer Inst 82: 1247-1259, 1990].
AB - Microtubules are among the most strategic subcellular targets of anticancer chemotherapeutics. Despite this fact, new antimicrotubule agents that possess unique mechanisms of cytotoxic action and have broader antineoplastic spectra than the vinca alkaloids have not been introduced over the last several decades-until the recent development of taxol. Unlike classical antimicrotubule agents like colchicine and the vinca alkaloids, which induce depolymerization of microtubules, taxol induces tubulin polymerization and forms extremely stable and nonfunctional microtubules. Taxol has demonstrated broad activity in preclinical screening studies, and antineoplastic activity has been observed in several classically refractory tumors. These tumors include cisplatin-resistant ovarian carcinoma in phase II trials and malignant melanoma and non-small cell lung carcinoma in phase I studies. Taxol's structural complexity has hampered the development of feasible processes for synthesis, and its extreme scarcity has limited the use of a conventional, broad-scale screening approach for evaluation of clinical antitumor activity. However, taxol's unique mechanism of action, its spectrum of preclinical antitumor activity, and tumor responses in early clinical trials have generated renewed interest in pursuing its development. [J Natl Cancer Inst 82: 1247-1259, 1990].
UR - http://www.scopus.com/inward/record.url?scp=0025333168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025333168&partnerID=8YFLogxK
U2 - 10.1093/jnci/82.15.1247
DO - 10.1093/jnci/82.15.1247
M3 - Review article
C2 - 1973737
AN - SCOPUS:0025333168
SN - 0027-8874
VL - 82
SP - 1247
EP - 1259
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
IS - 15
ER -